Aars Hot Topics Member Newsletter
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Proper Preop Makes for Easier Toenail Surgery
April 15, 2007 • www.familypracticenews.com Skin Disorders 25 Proper Preop Makes for Easier Toenail Surgery BY JEFF EVANS sia using a digital block or a distal approach to take ef- Senior Writer fect. Premedication with NSAIDs, codeine, or dextro- propoxyphene also may be appropriate, he said. WASHINGTON — Proper early management of in- To cut away the offending section of nail, an English grown toenails may help to decrease the risk of recur- anvil nail splitter is inserted under the nail plate and the rence whether or not surgery is necessary, Dr. C. Ralph cut is made all the way to the proximal nail fold. The hy- Daniel III said at the annual meeting of the American pertrophic, granulated tissue should be cut away as well. Academy of Dermatology. Many ingrown toenails are recurrent, so Dr. Daniel per- “An ingrown nail is primarily acting as a foreign-body forms a chemical matricectomy in nearly all patients after reaction. That rigid spicule penetrates soft surrounding tis- making sure that the surgical field is dry and bloodless. sue” and produces swelling, granulation tissue, and some- The proximal nail fold can be flared back to expose more times a secondary infection, said Dr. Daniel of the de- of the proximal matrix if necessary. Dr. Daniel inserts a Cal- partments of dermatology at the University of Mississippi, giswab coated with 88% phenol or 10% sodium hydroxide Jackson, and the University of Alabama, Birmingham. and applies the chemical for 30 seconds to the portion of For the early management of stage I ingrown toenails the nail matrix that needs to be destroyed. -
Clinical Features of the SAPHO Syndrome and Their Role in Choosing the Therapeutic Approach: Report of Four Patients and Review of the Literature
Acta Dermatovenerol Croat 2014;22(3):180-188 CLINICAL ARTICLE Clinical Features of the SAPHO Syndrome and their Role in Choosing the Therapeutic Approach: Report of Four Patients and Review of the Literature Branimir Anić, Ivan Padjen, Miroslav Mayer, Dubravka Bosnić, Mislav Cerovec Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb School of Medicine, University Hospital Centre Zagreb, Croatia Corresponding author: SUMMarY Although the SAPHO (synovitis, acne, pustulosis, hyper- Ivan Padjen, MD ostosis, osteitis) syndrome was defined as a distinct entity more than 20 years ago, its classification within the spectrum of inflammatory Department of Internal Medicine rheumatic diseases and the proper therapeutic approach are still a Division of Clinical Immunology and matter of debate. We present four patients diagnosed with the SAPHO Rheumatology syndrome treated and followed-up in our Department, demonstrating the diversity of their clinical courses and their responses to different University of Zagreb School of Medicine therapeutic approaches. We also review the clinical, laboratory, and University Hospital Centre zagreb imaging features of the SAPHO syndrome described in the relevant Kišpatićeva 12 literature. Despite the growing quantity of published data on the clini- 10000 Zagreb, Croatia cal features of the syndrome and the recognition of two disease pat- terns (inflammatory and bone remodeling disease), it is still not clear [email protected] whether these possible disease subsets require different therapeutic strategies. Tumor necrosis factor-alpha (TNF-α) inhibitors have been Received: April 8, 2014 suggested to be effective in patients with the inflammatory pattern, whereas bisphosphonates seem to be effective in patients with bone Accepted: July 10, 2014 remodeling disease; however, this is still a hypothesis not yet confirmed by adequately designed clinical studies. -
Acne Class Update
© Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-2596 Drug Class Update with New Drug Evaluation: Acne Drugs Date of Review: June 2020 Date of Last Review: November 2018 Dates of Literature Search: 08/03/2018 - 12/26/2019 Generic Name: Trifarotene Brand Name (Manufacturer): Aklief® (Galderma Laboratories, LP) Dossier Received: no Current Status of PDL Class: See Appendix 1. Purpose for Class Update: The acne class has had one new approval, trifarotene cream, and several new product formulations since it was last reviewed in 2018. The purpose of this update is to evaluate new comparative evidence for trifarotene cream for the treatment of acne vulgaris and any new data on comparative efficacy or harms in the acne class since the previous update. Acne conglobata, acne fulminans, and severe cystic acne are covered conditions under the Oregon Health Plan (OHP). Research Questions: 1. What is the comparative efficacy and effectiveness of treatments for severe acne (topical agents of adapalene, adapalene/benzoyl peroxide, tretinoin, tazarotene, benzoyl peroxide, salicylic acid, dapsone, azelaic acid, clindamycin, erythromycin, minocycline, sulfacetamide, trifarotene; oral systemic antibiotics of doxycycline, minocycline, tetracycline, azithromycin, erythromycin, clindamycin, trimethoprim, and sulfamethoxazole/trimethoprim; hormonal agents of oral contraceptives and spironolactone; and oral isotretinoin)? 2. What are the comparative harms of treatments for severe acne? 3. Are there subpopulations of patients in which a particular treatment for severe acne would be more effective or associated with less harm? Conclusions: There are no new high-quality clinical practice guidelines which have evaluated comparative efficacy and safety of treatments for acne vulgaris. -
Aars Hot Topics Member Newsletter
AARS HOT TOPICS MEMBER NEWSLETTER American Acne and Rosacea Society 201 Claremont Avenue • Montclair, NJ 07042 (888) 744-DERM (3376) • [email protected] www.acneandrosacea.org Like Our YouTube Page We encourage you to TABLE OF CONTENTS invite your colleagues and patients to get active in AARS in the Community the American Acne & Don’t forget to attend the 14th Annual AARS Networking Reception tonight! ........... 2 Rosacea Society! Visit Our first round of AARS Patient Videos are being finalized now ............................... 2 www.acneandrosacea.org Save the Date for the 8th Annual AARS Scientific Symposium at SID ..................... 2 to become member and Please use the discount code AARS15 for 15% off of registration to SCALE ........... 2 donate now on www.acneandrosacea.org/ Industry News donate to continue to see Ortho Dermatologics launches first cash-pay prescription program in dermatology . 2 a change in acne and Cutera to unveil excel V+ next generation laser platform at AAD Annual Meeting ... 3 rosacea. TARGET PharmaSolutions launches real-world study .............................................. 3 New Medical Research Epidemiology and dermatological comorbidity of seborrhoeic dermatitis ................... 4 A novel moisturizer with high SPF improves cutaneous barrier function .................... 5 Randomized phase 3 evaluation of trifarotene 50 μG/G cream treatment ................. 5 Open-label, investigator-initiated, single site exploratory trial..................................... 6 Erythematotelangiectatic -
12.2% 116000 120M Top 1% 154 3800
We are IntechOpen, the world’s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our authors are among the 154 TOP 1% 12.2% Countries delivered to most cited scientists Contributors from top 500 universities Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI) Interested in publishing with us? Contact [email protected] Numbers displayed above are based on latest data collected. For more information visit www.intechopen.com 5 Expression of Tumor Necrosis Factor-Alpha (TNF-TNF-Converting Enzyme and Matrix Metalloproteinase-3 in SAPHO Syndrome Synovium - A Rare Case Accompanied by Acrodermatitis Continua of Hallopeau: A Case Report and Review of Anti-TNF-Therapy Koichiro Komiya1, Nobuki Terada1, Yoshikazu Mizoguchi2 and Harumoto Yamada3 1Department of Orthopaedic Surgery, Fujita Health University Second Hospital 2Department of Pathology, Fujita Health University Second Hospital 3Department of Orthopaedic Surgery, Fujita Health University Japan 1. Introduction Synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome is a rare disorder characterized by osteoarticular and dermatological manifestations. The denotation was first proposed by Chamot et al. in 1987 after investigation of 85 cases (Chamot et al., 1987). The most common site of SAPHO syndrome is the upper anterior chest wall, characterized by predominantly osteosclerotic lesions and hyperostosis. The axial skeleton and peripheral bones can be involved. Peripheral synovitis is also common. Skin manifestations include palmoplantar pustulosis (PPP), severe acne and various patterns of psoriasis. The pathogenesis of SAPHO syndrome has not been determined. -
DRUG and MEDICAL DEVICE HIGHLIGHTS Helping You Maintain and Improve Your Health 2019
DRUG AND MEDICAL DEVICE HIGHLIGHTS Helping you maintain and improve your health 2019 DRUG AND MEDICAL DEVICE HIGHLIGHTS 2019 Helping you maintain and improve your health Learn about the new drugs and medical devices that Health Canada approved for sale in Canada, the information we published about potential safety issues, and our other accomplishments in 2019. Health Canada is the federal department responsible for helping the people of Canada maintain and improve their health. Health Canada is committed to improving the lives of all of Canada’s people and to making this country’s population among the healthiest in the world as measured by longevity, lifestyle and effective use of the public health care system. Également disponible en français sous le titre : Préserver et améliorer votre santé : Faits saillants sur les médicaments et les instruments médicaux 2019 To obtain additional information, please contact: Health Canada Address Locator 0900C2 Ottawa, ON K1A 0K9 Tel.: 613-957-2991 Toll free: 1-866-225-0709 Fax: 613-941-5366 TTY: 1-800-465-7735 E-mail: [email protected] © Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2020 Publication date: May 2020 This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged. Cat.: H161-11E-PDF ISSN: 2562-9816 Pub.: 190484 CONTENTS WELCOME TO OUR 2019 HIGHLIGHTS REPORT ..........................................................................................1 MESSAGE FROM THE CHIEF MEDICAL -
19F Henry Ford Health System Publication List – May 2021 This
19f Henry Ford Health System Publication List – May 2021 This bibliography aims to recognize the scholarly activity and provide ease of access to journal articles, meeting abstracts, book chapters, books and other works published by Henry Ford Health System personnel. Searches were conducted in PubMed, Embase, and Web of Science during the month, and then imported into EndNote for formatting. There are 144 unique citations listed this month, with 8 articles and 5 conference abstracts on COVID-19. Articles are listed first, followed by conference abstracts, books and book chapters, and a bibliography of publications on COVID-19. Because of various limitations, this does not represent an exhaustive list of all published works by Henry Ford Health System authors. Click the “Full Text” link to view the articles to which Sladen Library provides access. If the full- text of the article is not available, you may request it through ILLiad by clicking on “Request Article,” or calling us at (313) 916-2550. If you would like to be added to the monthly email distribution list to automatically receive a PDF of this bibliography, or you have any questions or comments, please contact [email protected]. If your published work has been missed, please use this form to notify us for inclusion on next month’s list. All articles and abstracts listed here are deposited into Scholarly Commons, the HFHS institutional repository. Jump to: Articles Administration Neurology Allergy and Immunology Neurosurgery Anesthesiology Obstetrics, Gynecology and Women’s Behavioral -
2020 Research Annual Report Table of Contents
2020 RESEARCH ANNUAL REPORT TABLE OF CONTENTS PART I – INTERNAL MEDICINE DEPARTMENT ALLERGY AND IMMUNOLOGY ...................................................................................... 1 CARDIOLOGY/CARDIOVASCULAR RESEARCH…………………………………………..2 ENDOCRINOLOGY AND METABOLISM ........................................................................ 3 GASTROENTEROLOGY ................................................................................................ 5 HYPERTENSION AND VASCULAR RESEARCH……………………………………….…...6 PULMONARY……………………………………………………………………………………10 SLEEP MEDICINE………………………………………………………………………………10 GENERAL INTERNAL MEDICINE…………………………………………………….………12 HEMATOLOGY/ONCOLOGY………………………………………………………………….12 PART II – ALL OTHER CLINICAL DEPARTMENTS DERMATOLOGY ......................................................................................................... .14 EMERGENCY MEDICINE……………………………………………………………………..17 NEUROLOGY…………………………………………………………………………………...19 NEUROSURGERY……………………………………………………………………………… ORTHOPAEDICS/BONE & JOINT…………………………………………………………….31 OTOLARYNGOLOGY………………………………………………………………………… .36 PATHOLOGY ................................................................................................................ .36 PEDIATRICS…………………………………………………………………………………….37 PSYCHIATRY/BEHAVORIAL HEALTH………………………………………………………38 RADIATION ONCOLOGY ............................................................................................. 39 UROLOGY………………………………………………………………………………………40 WOMEN’S HEALTH……………………………………………………………………………42 i PART III POPULATION -
A20-73 Trifarotene (Acne Vulgaris) – Benefit Assessment According to §35A Social Code Book V1
IQWiG Reports – Commission No. A20-73 Trifarotene (acne vulgaris) – Benefit assessment according to §35a Social Code Book V1 Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Trifaroten (Acne vulgaris) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 November 2020). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract of dossier assessment A20-73 Version 1.0 Trifarotene (acne vulgaris) 12 November 2020 Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Trifarotene (acne vulgaris) – Benefit assessment according to §35a Social Code Book V Commissioning agency Federal Joint Committee Commission awarded on 13 August 2020 Internal Commission No. A20-73 Address of publisher Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: [email protected] Internet: www.iqwig.de Institute for Quality and Efficiency in Health Care (IQWiG) - i - Extract of dossier assessment A20-73 Version 1.0 Trifarotene (acne vulgaris) 12 November 2020 Medical and scientific advice . Prof. Dr. med. Dr. rer. nat. Enno Schmidt, University Hospital Schleswig-Holstein, Lübeck, Germany IQWiG thanks the medical and scientific advisor for his contribution to the dossier assessment. However, the advisor was not involved in the actual preparation of the dossier assessment. The responsibility for the contents of the dossier assessment lies solely with IQWiG. IQWiG employees involved in the dossier assessment . Anke Penno . Katharina Biester . Moritz Felsch . -
SAPHO Syndrome from Hidradenitis Suppurativa Veesta Falahati, Msc, MD and Paul B
JGIM CLINICAL PRACTICE Clinical Images SAPHO Syndrome from Hidradenitis Suppurativa Veesta Falahati, MSc, MD and Paul B. Aronowitz, MD Department of Internal Medicine, University of California, Davis Medical Center, Sacramento, CA, USA. KEY WORDS: clinical image; dermatology; diagnosis; rheumatology. SAPHO syndrome is a poorly understood inflammatory – disorder thought to be an autoimmune reaction provoked by J Gen Intern Med 35(4):1307 8 2 DOI: 10.1007/s11606-019-05131-2 an indolent inflammatory process (in this case, HS). The © Society of General Internal Medicine 2020 acronym SAPHO represents the variable presence of synovi- tis, acne, pustulosis, hyperostosis, and osteitis seen in this syndrome.3 The most common skin lesion is palmoplantar pustulosis. Osteoarticular manifestations include osteitis, hy- perostosis synovitis, arthropathy, and enthesopathy.3 Involve- 36-year-old man with 10 years of hidradenitis ment of bone and joints of the anterior chest wall is felt to be A suppurativa (HS) presented with worsened HS and joint highly characteristic. Treatment of SAPHO is variable de- pain in both hands after stopping adalimumab therapy 1 year pending on the case presentation. earlier. Examination revealed a temperature of 38.2 °C, HS lesions draining purulent material over the chest (Fig. 1), and erosions in bilateral proximal interphalangeal joints (Fig. 2). His white blood cell count was 21,000/μL and hand radio- graphs were consistent with inflammatory arthropathy. He received a diagnosis of hidradenitis suppurativa with superimposed cellulitis in the setting of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome. Treatment included antibiotics and wound care. He resumed adalimumab and started doxycycline for long-term suppres- sive therapy.1 He failed to improve, and his treatment was escalated from adalimumab to secukinumab. -
Dermatology Gp Booklet
These guidelines are provided by the Departments of Dermatology of County Durham and Darlington Acute Hospitals NHS Trust and South Tees NHS Foundation Trust, April 2010. More detailed information and patient handouts on some of the conditions may be obtained from the British Association of Dermatologists’ website www.bad.org.uk Contents Acne Alopecia Atopic Eczema Hand Eczema Intertrigo Molluscum Contagiosum Psoriasis Generalised Pruritus Pruritus Ani Pityriasis Versicolor Paronychia - Chronic Rosacea Scabies Skin Cancers Tinea Unguium Urticaria Venous Leg Ulcers Warts Topical Treatment Cryosurgery Acne Assess severity of acne by noting presence of comedones, papules, pustules, cysts and scars on face, back and chest. Emphasise to patient that acne may continue for several years from teens and treatment may need to be prolonged. Treatment depends on the severity and morphology of the acne lesions. Mild acne Comedonal (Non-inflammatory blackheads or whiteheads) • Benzoyl peroxide 5-10% for mild cases • Topical tretinoin (Retin-A) 0.01% - 0.025% or isotretinoin (Isotrex) Use o.d. but increase to b.d. if tolerated. Warn the patient that the creams will cause the skin to become dry and initially may cause irritation. Stop if the patient becomes pregnant- although there is no evidence of harmful effects • Adapalene 0.1% or azelaic acid 20% may be useful alternatives Inflammatory (Papules and pustules) • Any of the above • Topical antibiotics – Benzoyl peroxide + clindamycin (Duac), Erythromycin + zinc (Zineryt) Erythromycin + benzoyl peroxide (Benzamycin gel) Clindamycin (Dalacin T) • Continue treatment for at least 6 months • In patients with more ‘stubborn’ acne consider a combination of topical antibiotics o.d with adapalene, retinoic acid or isotretinoin od. -
213433Orig1s000
CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213433Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA/BLA Multidisciplinary Review and Evaluation: NDA 213433 WINLEVI (clascoterone) cream, 1% NDA Multidisciplinary Review and Evaluation Application Type NME- In “The Program” Application Number(s) NDA 213433 Priority or Standard Standard Submit Date(s) August 19, 2019 Received Date(s) August 27, 2019 PDUFA Goal Date August 27, 2020 Division/Office Shari Targum, Deputy Director, Division of Dermatology and Dentistry Julie Beitz, Director Office of Immunology and Inflammation Review Completion Date Established/Proper Name Clascoterone cream, 1% (Proposed) Trade Name WINLEVI Pharmacologic Class NME Code Name N/A Applicant Cassiopea SpA Dosage Form Topical cream Applicant proposed Dosing Apply a thin layer (approximately 1 gram) to affected area Regimen twice daily (morning and evening) Applicant Proposed For the treatment of acne vulgaris in patients 9 years of age Indication(s)/Population(s) and older Applicant Proposed SNOMED CT Indication Disease Term for Each Proposed Indication Recommendation on Regulatory Action Approval Recommended For the treatment of acne vulgaris in patients 12 years of age Indication(s)/Population(s) and older (if applicable) Recommended SNOMED CT Indication Disease Term for Each Indication (if applicable) Recommended Dosing Apply a thin layer (approximately 1 gram) to affected area Regimen twice daily (morning and